IL305861A - Treatment for sickle cell anaemia - Google Patents

Treatment for sickle cell anaemia

Info

Publication number
IL305861A
IL305861A IL305861A IL30586123A IL305861A IL 305861 A IL305861 A IL 305861A IL 305861 A IL305861 A IL 305861A IL 30586123 A IL30586123 A IL 30586123A IL 305861 A IL305861 A IL 305861A
Authority
IL
Israel
Prior art keywords
treatment
sickle cell
cell anaemia
anaemia
sickle
Prior art date
Application number
IL305861A
Other languages
Hebrew (he)
Inventor
Mukul Jain
Amit Joharapurkar
Vishal Patel
Original Assignee
Zydus Lifesciences Ltd
Mukul Jain
Amit Joharapurkar
Vishal Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Lifesciences Ltd, Mukul Jain, Amit Joharapurkar, Vishal Patel filed Critical Zydus Lifesciences Ltd
Publication of IL305861A publication Critical patent/IL305861A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
IL305861A 2021-03-19 2022-03-17 Treatment for sickle cell anaemia IL305861A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121011754 2021-03-19
PCT/IB2022/052429 WO2022195532A1 (en) 2021-03-19 2022-03-17 Treatment for sickle cell anaemia

Publications (1)

Publication Number Publication Date
IL305861A true IL305861A (en) 2023-11-01

Family

ID=83322118

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305861A IL305861A (en) 2021-03-19 2022-03-17 Treatment for sickle cell anaemia

Country Status (4)

Country Link
EP (1) EP4308120A1 (en)
BR (1) BR112023018949A2 (en)
IL (1) IL305861A (en)
WO (1) WO2022195532A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3357911T (en) * 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
TR201802305T4 (en) * 2012-12-24 2018-03-21 Cadila Healthcare Ltd Quinolone derivatives.
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions for use in methods of treatment of hemoglobin disorders
US10899713B2 (en) * 2018-05-25 2021-01-26 Cadila Healthcare Limited Process for the preparation of quinolone based compounds

Also Published As

Publication number Publication date
BR112023018949A2 (en) 2023-10-17
EP4308120A1 (en) 2024-01-24
WO2022195532A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
EP4096671A4 (en) Combination therapy for treating abnormal cell growth
MD20130089A2 (en) Multiple myeloma treatment
GB2602050B (en) Energy harvesting assemblies
IL281032A (en) Pde9 inhibitors for treating sickle cell disease
IL310477A (en) Combination therapy for treating abnormal cell growth
GB202013431D0 (en) Components for Batteries
GB202007321D0 (en) T cells
GB202006820D0 (en) Cell
EP4135110A4 (en) Battery cabinet
IL305861A (en) Treatment for sickle cell anaemia
EP3773637A4 (en) Methods for treating sickle cell disease
ZA202107544B (en) Pde9 inhibitors for treating sickle cell disease
SG11202003493VA (en) Composition for treating skin cell damage caused by fine dust, containing green tea-derived lactic acid bacteria
GB2598344B (en) Components for batteries
GB202102996D0 (en) Components for batteries
GB202013433D0 (en) Components for batteries
EP4055145A4 (en) Use of veto cells for the treatment of sickle cell disease
GB201918313D0 (en) Cells for treating cancer
GB202005216D0 (en) Cell
EP4046636A4 (en) Composition for treating spinal cord injury, comprising stem cells treated with novel compound
GB2602048B (en) Energy harvesting assemblies
GB2604369B (en) Components for Batteries
AU2022376939A1 (en) Combination therapy for treating abnormal cell growth
GB202017618D0 (en) Antibacterial methods & cells
ZA202108724B (en) Bedstand for whole-feed rice-wheat combine harvester